A Phase 3 interventional study of Lenalidomide: Double-blind Induction and Melphalan in Newly Diagnosed Multiple Myeloma, sponsored by Celgene Corporation. Completed at 98 sites in 22 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.
Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 21st largest by enrollment, is one of 15 that started in 2007, is one of 44 in phase 3, and was the 19th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
University of Leeds · Sites in United Kingdom
Ages 18+
Eden Biltibo · Sites in United States
Ages 18–70
AbbVie · Sites in United States, France, Japan and 1 more country
Ages 18+
Dickran Kazandjian, MD · Sites in United States
University of Miami · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
249 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 164 · Phase 3 47 · Phase 4 10
First in 2002; this study’s year is marked. 15 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 459 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 50 across the 249 interventional studies. Of the 155 that completed or were terminated, 81 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 249 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
149 studies in Multiple Myeloma by Bristol-Myers Squibb: 9 open now, 18 under way, 6 of them phase 3. Of 120 finished, 43 (36%) have results posted.
Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2007, is one of 30 in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Multiple Myeloma studies by the year they started, since 2001.
14 of the studies testing lenalidomide in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01863550Phase 3ECOG-ACRIN Cancer Research GroupBortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | 2026-12-31 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04009109Alliance Foundation Trials, LLC.Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | 2026-12 |
| NCT03829371University of Turin, ItalySTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | 2027-01-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 249 studies testing lenalidomide in Multiple Myeloma, from their registry updates:
Among Bristol-Myers Squibb’s 149 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.
The three phases for the study as originally defined and as represented in the results of 11 May 2010 are:
Double-blind Treatment Phase: Induction Melphalan/prednisone and lenalidomide 10 mg (MPR) (2 treatment arms), or melphalan/prednisone and placebo (MPp) (1 treatment arm) for up to 9 cycles. If disease progression, subjects have the option to enter into the Open-Label Extension Phase. There is also an option to enter into the Follow-Up Phase. If the disease has not progressed, subject can continue on blinded therapy into Maintenance.
Double-blind Treatment Phase: Maintenance One MPR treatment arm (MPR+R) will continue taking lenalidomide 10 mg in Maintenance. The other MPR treatment arm (MPR+p) will take placebo in Maintenance. The MP p treatment arm will take placebo in Maintenance (MPp+p). If disease progression, subjects have the option to enter the Open-Label Extension Phase to obtain treatment with lenalidomide, or to enter into the Follow-up Phase.
Open-label Extension Phase:
Treatment consists of oral lenalidomide (up to 25 mg) with or without dexamethasone until disease progression or treatment is discontinued for any reason until all study subjects are followed for at least 5 years from the date of randomization or have died. Subjects who discontinue from the Open-Label Extension Phase prior to completing a total of 5 years in the study will enter the Follow-up Phase.
Follow-up Phase:
Subjects are followed for overall survival and subsequent anti-myeloma treatment regimens until all subjects in this study are followed for at least 5 years from randomization or have died.
The pre-planned interim analysis for the Independent Data Monitoring Committee (IDMC) showed that the difference in progression-free survival (PFS) between treatment arms MPR+R and MPp+p (the defined primary comparative analysis for this study) surpassed the pre-specified O'Brien-Fleming boundary for superiority. The IDMC recommended the release of this information to the sponsor and also recommended that all patient and physician study participants receive information concerning the full findings of the MM-015 interim analysis. Therefore, due to these recommendations from the IDMC, treatment-arm codes were sent to the clinical trial centers to unblind the treatment arms of their study subjects once the amended protocol was reviewed and approved by the respective country Health Authorities and Ethics Committees. Subject participation in the MM-015 study continued after unblinding to obtain long-term data for all study endpoints, including overall survival.
When the study was unblinded, subjects still on protocol therapy had completed the Double-Blind Induction, and were on monotherapy in Double-Blind Maintenance. Subjects in arm MPR+R continued their monotherapy on lenalidomide. Subjects in arms MPR+p and MPp+p discontinued their placebo monotherapy and went into an observation period in which no antimyeloma therapy was taken. If disease progressed for any subject, the investigator had the option of entering the subject in Open Label Extension Phase to receive lenalidomide therapy (up to 25 mg daily) or the Follow-up Phase. All subjects were to be followed for at least 5 years from the start of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
MM diagnostic criteria (all of next 3 required)
Women of (WCBP) must:
a. Have a negative medically supervised pregnancy test prior to the start of study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy. This applies even if the subject practices and continues sexual abstinence.
b Either commit to continued abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting study drug, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.
Males Subjects must:
All subjects must
Female Subjects:
Females of childbearing potential (FCBP) with regular cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study discontinuation, and at day 28 following discontinuation from the study. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days and then every 14 days while on study, at study discontinuation, and at days 14 and 28 following discontinuation from the study.
In addition to the required pregnancy testing, the Investigator must confirm with FCBP that she is continuing to use two reliable methods of birth control at each visit. Counseling about pregnancy precautions and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood.
Pregnancy testing and counseling must be performed if a subject misses her period or if her pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be discontinued during this evaluation.
Females must agree to abstain from breastfeeding during study participation and for at least 28 days after the discontinuation from the study.
Male Subjects:
Counseling about the requirement for latex condom use during sexual contact with females of childbearing potential and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood, sperm, or semen.
If pregnancy or a positive pregnancy test does occur in a study subject or the partner of a study subject during study participation, study drug must be immediately discontinued.
Exclusion Criteria
Any of the following laboratory abnormalities:
(ANC) \< 1,500 cells/mL (1.5*10\^9/L) count \< 75,000 cells/uL (75*10\^9/L) for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; but platelet count \<30,000/uL for subjects in whom >= 50% of bone marrow nucleated cells are plasma cells \< 8.0 g/dL (80 g/L) Serum creatinine > 2.5 mg/dL (221 µmol/L) Serum (SGOT/AST) or alanine aminotransferase (SGPT/ALT) > 3.0 times (ULN)
Prior history of , other than multiple myeloma, unless the subject has been free of the disease for greater than or equal to 3 years.
Exceptions include the following:
Basal cell carcinoma of the skin Squamous cell carcinoma of the skin Carcinoma in situ of the cervix Carcinoma in situ of the breast Incidental histologic finding of prostate cancer (TNM Classification of Malignant Tumours (TNM) stage of T1a or T1b)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
Drug: Lenalidomide: Double-blind Induction · Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Lenalidomide: Double-blind Maintenance · Drug: Lenalidomide: Open-label
Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
Drug: Lenalidomide: Double-blind Induction · Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Placebo · Drug: Lenalidomide: Open-label
Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
Drug: Melphalan · Drug: Prednisone · Drug: Aspirin · Drug: Placebo · Drug: Lenalidomide: Open-label
Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Also known as: Revlimid
Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Also known as: Alkeran
Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms. Double-blind maintenance: at the investigator's discretion
Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles. Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
Also known as: Revlimid
Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
Also known as: Revlimid
Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)
Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: up to 165 weeks
Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)
Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: Approximately week 37 (start of cycle 10) to week 165
Kaplan Meier Estimates of Overall Survival (OS)
Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.
Time frame: up to 177 weeks
Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)
Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: up to 165 weeks
Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period
Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus \>=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).
Time frame: Up to 165 weeks
Time to First Response
Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.
Time frame: Up to 66 weeks
Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)
Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
Time frame: Up to 149 weeks
Kaplan Meier Estimates for Time to Next Antimyeloma Therapy
Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.
Time frame: Up to 168 weeks
Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period
Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.
Time frame: Up to 169 weeks (Double-blind therapy period plus 4 weeks)
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale
Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.
Time frame: Baseline (Day 0), Months 4, 7, 10, 13, 16
Data represents a May 11, 2010 data cut-off. The study is ongoing.
| Milestone | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Started | 152 | 153 | 154 |
| Safety population | 150 | 152 | 153 |
| Completed | 0 | 0 | 0 |
| Not completed | 152 | 153 | 154 |
| Withdrew: Ongoing in double-blind treatment | 45 | 24 | 18 |
| Withdrew: Adverse event | 31 | 27 | 12 |
| Withdrew: Disease progression | 47 | 81 | 102 |
| Withdrew: Lack of efficacy | 1 | 4 | 2 |
| Withdrew: Withdrawal by subject | 15 | 9 | 10 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Death | 4 | 4 | 4 |
| Withdrew: Protocol violation | 1 | 0 | 2 |
| Withdrew: Other | 7 | 4 | 4 |
| Milestone | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Started | 19 | 47 | 72 |
| Completed | 0 | 0 | 0 |
| Not completed | 19 | 47 | 72 |
| Withdrew: Ongoing in open label period | 7 | 15 | 25 |
| Withdrew: Adverse event | 1 | 3 | 7 |
| Withdrew: Disease progression | 8 | 23 | 26 |
| Withdrew: Withdrawal by subject | 2 | 3 | 3 |
| Withdrew: Death | 1 | 2 | 4 |
| Withdrew: Other | 0 | 1 | 7 |
| Milestone | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Started | 75 | 90 | 88 |
| Completed | 0 | 0 | 0 |
| Not completed | 75 | 90 | 88 |
| Withdrew: Ongoing in follow-up period | 52 | 51 | 60 |
| Withdrew: Death | 21 | 31 | 24 |
| Withdrew: Lost to follow-up | 2 | 8 | 4 |
Data as of 11 May 2010 cutoff. PFS was calculated as the time from randomization to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC) | 136.1 (86.14 to NA) | 62.1 (56.14 to 72.14) | 56.1 (52.14 to 68.14) |
Data as of 11 May 2010 cutoff. PFS calculated from the start of the Maintenance period to the earlier of the first documentation of progressive disease (PD) as determined by the CAC, or death on study due to any cause. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | MPR+R | MPR+p |
|---|---|---|
| Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC) | 112.0 (83.29 to NA) | 32.3 (23.57 to 52.14) |
Data as of 11 May 2010 cutoff. Overall survival (OS) was defined as the time between randomization and death. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who were lost to follow-up prior to the end of the trial, or who were withdrawn from the trial, were censored at the time of last contact. Participants who were still being treated were censored at the last available date available, or clinical cut-off date, if it was earlier.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Kaplan Meier Estimates of Overall Survival (OS) | NA (NA to NA) | NA (148.43 to NA) | NA (NA to NA) |
Data as of 11 May 2010 cutoff. TTP was the time between randomization and disease progression as determined by the CAC. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC) | 148.1 (100.00 to NA) | 62.7 (57.14 to 74.14) | 61.3 (52.29 to 70.14) |
Data as of 11 May 2010 cutoff. Best response was determined by the Central Assessment Committee (CAC) based on the European Group for Blood and Marrow Transplantation (EBMT) criteria: Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of bone lesions, plus other factors); Partial Response (PR)-not all CR criteria, plus \>=50% reduction in serum monoclonal paraprotein plus others; Stable Disease (SD)- not PR or PD; Progressive Disease (PD)- reappearance of monoclonal paraprotein, bone lesions, other; Not Evaluable (NE).
| participants | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Complete response (CR) | 15 | 5 | 5 |
| Partial response (PR) | 102 | 99 | 72 |
| Stable disease (SD) | 28 | 40 | 70 |
| Progressive disease (PD) | 0 | 2 | 0 |
| Response not evaluable (NE) | 7 | 7 | 7 |
Data as of 11 May 2010 cutoff. Time to first response was defined as the time from start of treatment until first response as assessed by the Central Assessment Committee (CMC) based on European Group for Blood and Marrow Transplantation (EBMT) criteria.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Time to First Response | 10.0 ± 7.40 | 9.3 ± 6.55 | 16.2 ± 11.59 |
Data as of 11 May 2010 cutoff. Duration of myeloma response was defined as the time from the initial response date to the earlier of progressive disease (PD) as determined by the CAC or death on study. PD was based on the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplant Registry/Autologous Bone Marrow Transplant Registry \[EBMT/IBMTR/ABMTR\] criteria. PD criteria includes increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC) | 121.6 (96.00 to NA) | 56.1 (52.14 to 64.29) | 55.4 (44.14 to 76.14) |
Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.
| weeks | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Kaplan Meier Estimates for Time to Next Antimyeloma Therapy | 128.9 (99.86 to NA) | 66.1 (60.14 to 76.00) | 66.3 (61.14 to 72.43) |
Data as of 11 May 2010 cutoff. Participant counts in different categories of TEAEs during the double-blind treatment period. A TEAE is as any AE occurring or worsening on or after the first treatment of any study drug, and within 30 days after the last dose of the last study drug. Severity grades according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE) on a 1-5 scale: Grade 1= Mild AE, Grade 2= Moderate AE, Grade 3= Severe AE, Grade 4= Life-threatening or disabling AE, Grade 5=Death related to AE. Dose reduction includes reduction with or without interruption.
| participants | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| >=1 adverse event (AE) | 150 | 151 | 153 |
| >=1 CTCAE grade 3-4 AE | 137 | 129 | 107 |
| >=1 CTCAE grade 5 AE | 7 | 6 | 7 |
| >=1 serious AE (SAE) | 66 | 62 | 56 |
| >=1 AE related to Lenaldomide/Placebo | 148 | 145 | 131 |
| >=1 AE related to Melphalan | 140 | 134 | 126 |
| >=1AE related to Prednisone | 87 | 94 | 93 |
| >=1 Grade 3-4 AE related to Lenaldomide/Placebo | 128 | 117 | 68 |
| >=1 Grade 3-4 AE related to Melphalan | 118 | 110 | 62 |
| >=1 Grade 3-4 AE related to Prednisone | 32 | 29 | 22 |
| >=1 Grade 5 AE related to Lenalidomide/Placebo | 3 | 2 | 2 |
| >=1 Grade 5 AE related to Melphalan | 3 | 1 | 3 |
| >=1 Grade 5 AE related to Prednisone | 1 | 1 | 1 |
| >=1 SAE related to Lenalidomide/Placebo | 38 | 32 | 11 |
| >=1 SAE related to Melphalan | 27 | 24 | 11 |
| >=1 SAE related to Prednisone | 19 | 16 | 5 |
| >=1 AE leading to Lenalidomide/Placebo withdrawal | 26 | 24 | 14 |
| >=1 AE leading to Melphalan withdrawal | 20 | 19 | 10 |
| >=1 AE leading to Prednisone withdrawal | 20 | 19 | 10 |
| >=1 AE leading to Lenalidomide/Plac dose reduction | 71 | 70 | 26 |
| >=1 AE leading to Melphalan dose reduction | 47 | 58 | 21 |
| >=1 AE leading to Prednisone dose reduction | 15 | 7 | 5 |
| >=1 AE leading to Lenalidomide/Plac dose interrupt | 92 | 82 | 51 |
| >=1 AE leading to Melphalan dose interruption | 5 | 1 | 0 |
| >=1 AE leading to Prednisone dose interruption | 28 | 39 | 15 |
Data as of 11 May 2010 cutoff. EORTC QLC-C30 is a 30-item questionnaire to assess the quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,121,125) | 2.3 ± 26.13 | 5.6 ± 18.86 | 6.1 ± 19.41 |
| Cycle 7 - approximately Month 7 (n=96,108,110) | 8.0 ± 24.95 | 8.1 ± 22.48 | 4.2 ± 23.92 |
| Cycle 10 - approximately Month 10 (n=84,86,96) | 12.4 ± 25.33 | 8.8 ± 24.70 | 6.2 ± 24.60 |
| Cycle 13 - approximately Month 13 (n=70,70,82) | 7.6 ± 28.32 | 8.8 ± 24.02 | 5.4 ± 22.80 |
| Cycle 16 - approximately Month 16 (n=61,50,62) | 10.7 ± 25.28 | 7.2 ± 26.29 | 8.1 ± 25.11 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | 1.9 ± 23.72 | 3.3 ± 21.64 | 4.5 ± 18.68 |
| Cycle 7 - approximately Month 7 (n=100,112,112) | 8.2 ± 22.71 | 8.1 ± 20.54 | 2.7 ± 23.20 |
| Cycle 10 - approximately Month 10 (n=88,95,96) | 8.9 ± 22.75 | 8.5 ± 25.62 | 5.1 ± 20.42 |
| Cycle 13 - approximately Month 13 (n=75,74,83) | 8.6 ± 24.04 | 9.7 ± 25.39 | 3.3 ± 20.30 |
| Cycle 16 - approximately Month 16 (n=64,53,63) | 10.0 ± 25.00 | 7.6 ± 22.66 | 1.1 ± 19.30 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,127,130) | 1.8 ± 33.18 | 3.0 ± 30.75 | 7.4 ± 26.34 |
| Cycle 7 - approximately Month 7 (n=99,112,113) | 5.7 ± 35.57 | 8.0 ± 32.42 | 6.9 ± 31.16 |
| Cycle 10 - approximately Month 10 (n=86,95,95) | 9.3 ± 35.76 | 7.5 ± 36.29 | 5.6 ± 31.29 |
| Cycle 13 - approximately Month 13 (n=74,74,82) | 9.7 ± 40.36 | 11.7 ± 33.42 | 5.7 ± 30.68 |
| Cycle 16 - approximately Month 16 (n=64,53,63) | 12.2 ± 40.09 | 8.5 ± 34.22 | 7.1 ± 31.93 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | 4.8 ± 25.00 | 2.7 ± 22.59 | 6.8 ± 18.75 |
| Cycle 7 - approximately Month 7 (n=98,111,112) | 8.8 ± 24.94 | 4.2 ± 20.38 | 5.0 ± 21.56 |
| Cycle 10 - approximately Month 10 (n=86,92,97) | 9.0 ± 23.28 | 1.6 ± 22.07 | 4.7 ± 22.05 |
| Cycle 13 - approximately Month 13 (n=73,73,83) | 8.2 ± 24.59 | 1.1 ± 21.78 | 6.6 ± 21.78 |
| Cycle 16 - approximately Month 16 (n=63,52,63) | 9.9 ± 23.23 | -0.2 ± 21.57 | 6.9 ± 19.72 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,128) | 0.3 ± 21.51 | -2.0 ± 21.33 | 1.3 ± 16.68 |
| Cycle 7 - approximately Month 7 (n=98,111,113) | 2.9 ± 22.31 | 0.1 ± 17.33 | 0.7 ± 18.42 |
| Cycle 10 - approximately Month 10 (n=87,92,97) | 1.0 ± 22.64 | -4.4 ± 19.89 | -2.7 ± 20.65 |
| Cycle 13 - approximately Month 13 (n=73,73,83) | -0.0 ± 21.34 | -3.0 ± 23.78 | -1.4 ± 17.69 |
| Cycle 16 - approximately Month 16 (n=63,52,63) | 0.3 ± 22.29 | -3.5 ± 27.48 | -4.0 ± 18.13 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,127) | 5.1 ± 35.05 | 0.3 ± 26.60 | 6.0 ± 22.78 |
| Cycle 7 - approximately Month 7 (n=98,111,112) | 8.3 ± 33.87 | 4.4 ± 24.48 | 6.1 ± 26.57 |
| Cycle 10 - approximately Month 10 (n=87,92,97) | 10.9 ± 34.27 | 4.5 ± 29.87 | 4.1 ± 27.22 |
| Cycle 13 - approximately Month 13 (n=72,73,83) | 11.8 ± 32.91 | 7.5 ± 29.80 | 6.2 ± 27.63 |
| Cycle 16 - approximately Month 16 (n=63,52,63) | 13.2 ± 33.35 | 6.1 ± 30.79 | 9.8 ± 28.66 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | -3.0 ± 25.61 | -5.5 ± 24.08 | -5.1 ± 24.33 |
| Cycle 7 - approximately Month 7 (n=100,112,110) | -7.6 ± 23.00 | -9.5 ± 25.97 | -5.7 ± 27.32 |
| Cycle 10 - approximately Month 10 (n=87,95,95) | -7.5 ± 27.31 | -7.5 ± 29.78 | -6.9 ± 28.31 |
| Cycle 13 - approximately Month 13 (n=74,74,82) | -7.1 ± 26.08 | -10.7 ± 30.33 | -7.5 ± 27.29 |
| Cycle 16 - approximately Month 16 (n=64,53,62) | -10.0 ± 26.86 | -9.7 ± 28.77 | -4.1 ± 26.34 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,130) | 3.3 ± 19.40 | -1.3 ± 17.14 | -0.0 ± 17.36 |
| Cycle 7 - approximately Month 7 (n=99,112,112) | 0.5 ± 14.57 | -0.7 ± 19.94 | 0.7 ± 14.73 |
| Cycle 10 - approximately Month 10 (n=87,95,97) | 1.9 ± 16.75 | -1.4 ± 19.40 | 0.3 ± 14.23 |
| Cycle 13 - approximately Month 13 (n=75,72,83) | 0.7 ± 13.55 | -3.0 ± 19.65 | -0.4 ± 12.48 |
| Cycle 16 - approximately Month 16 (n=64,52,62) | 1.0 ± 12.90 | -4.2 ± 18.65 | -1.3 ± 9.21 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=120,127,129) | -14.4 ± 32.76 | -13.8 ± 33.60 | -13.4 ± 29.32 |
| Cycle 7 - approximately Month 7 (n=100,112,113) | -17.8 ± 36.18 | -16.5 ± 33.45 | -11.5 ± 33.49 |
| Cycle 10 - approximately Month 10 (n=88,95,97) | -17.2 ± 34.78 | -15.6 ± 35.30 | -9.8 ± 31.71 |
| Cycle 13 - approximately Month 13 (n=74,74,83) | -13.7 ± 40.48 | -14.9 ± 33.28 | -12.1 ± 27.46 |
| Cycle 16 - approximately Month 16 (n=64,53,63) | -20.3 ± 33.92 | -11.0 ± 33.00 | -12.2 ± 29.96 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=117,126,126) | -2.6 ± 29.74 | -6.4 ± 32.04 | -0.0 ± 23.48 |
| Cycle 7 - approximately Month 7 (n=100,110,110) | -1.7 ± 28.18 | -8.5 ± 32.07 | 2.1 ± 20.82 |
| Cycle 10 - approximately Month 10 (n=86,93,96) | -4.3 ± 30.60 | -4.3 ± 35.87 | 3.8 ± 25.07 |
| Cycle 13 - approximately Month 13 (n=73,73,81) | -5.0 ± 30.26 | -2.3 ± 30.60 | -0.0 ± 22.35 |
| Cycle 16 - approximately Month 16 (n=62,53,62) | -3.2 ± 29.39 | -6.3 ± 32.07 | 1.6 ± 22.92 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=118,124,128) | 2.0 ± 33.56 | -1.6 ± 31.77 | -5.0 ± 27.77 |
| Cycle 7 - approximately Month 7 (n=100,109,111) | -1.0 ± 29.76 | -6.4 ± 27.02 | -5.7 ± 32.06 |
| Cycle 10 - approximately Month 10 (n=87,94,96) | -5.0 ± 28.99 | -2.5 ± 25.04 | -1.7 ± 32.58 |
| Cycle 13 - approximately Month 13 (n=75,73,83) | -4.9 ± 29.86 | 0.9 ± 29.38 | -6.8 ± 29.80 |
| Cycle 16 - approximately Month 16 (n=64,53,63) | -4.7 ± 32.46 | -0.6 ± 32.36 | -3.7 ± 31.18 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=119,125,130) | 1.7 ± 36.54 | 1.9 ± 34.73 | -5.6 ± 25.96 |
| Cycle 7 - approximately Month 7 (n=99,111,111) | -3.7 ± 33.64 | -5.7 ± 31.75 | -5.7 ± 27.66 |
| Cycle 10 - approximately Month 10 (n=87,93,96) | -5.0 ± 33.15 | -5.4 ± 29.20 | -8.0 ± 29.32 |
| Cycle 13 - approximately Month 13 (n=75,72,83) | -6.2 ± 36.23 | -8.8 ± 30.13 | -4.8 ± 32.15 |
| Cycle 16 - approximately Month 16 (n=64,52,63) | -7.8 ± 36.01 | -16.0 ± 35.24 | -6.4 ± 28.62 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=114,124,128) | -1.8 ± 34.31 | 4.8 ± 30.86 | -4.9 ± 27.45 |
| Cycle 7 - approximately Month 7 (n=96,111,112) | -3.5 ± 36.35 | 0.6 ± 30.14 | -2.7 ± 31.05 |
| Cycle 10 - approximately Month 10 (n=86,93,97) | -5.0 ± 34.88 | -1.1 ± 28.43 | -1.7 ± 26.95 |
| Cycle 13 - approximately Month 13 (n=73,73,81) | -5.0 ± 31.27 | -2.7 ± 28.74 | -3.3 ± 29.16 |
| Cycle 16 - approximately Month 16 (n=63,51,62) | -1.6 ± 31.36 | -5.2 ± 30.82 | -2.2 ± 32.44 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=115,125,124) | 2.3 ± 28.85 | 1.9 ± 24.06 | 3.2 ± 25.65 |
| Cycle 7 - approximately Month 7 (n=98,109,112) | 3.4 ± 25.54 | -1.2 ± 23.09 | 0.9 ± 22.13 |
| Cycle 10 - approximately Month 10 (n=87,92,95) | 1.1 ± 22.98 | 1.4 ± 20.91 | -0.0 ± 21.19 |
| Cycle 13 - approximately Month 13 (n=73,73,80) | 5.5 ± 30.43 | -1.4 ± 18.78 | 0.8 ± 18.35 |
| Cycle 16 - approximately Month 16 (n=63,52,61) | 10.6 ± 35.83 | 1.3 ± 19.75 | 0.5 ± 17.74 |
Data as of 11 May 2010 cutoff. EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=111,123,125) | 2.4 ± 24.91 | -1.1 ± 19.06 | -2.9 ± 18.93 |
| Cycle 7 - approximately Month 7 (n=94,111,112) | 2.1 ± 23.85 | -0.6 ± 28.07 | -2.1 ± 22.50 |
| Cycle 10 - approximately Month 10 (n=84,92,97) | 6.0 ± 21.44 | 0.7 ± 28.81 | -1.7 ± 19.47 |
| Cycle 13 - approximately Month 13 (n=70,72,83) | 4.8 ± 21.45 | -0.5 ± 28.80 | -4.0 ± 26.75 |
| Cycle 16 - approximately Month 16 (n=61,52,63) | 1.6 ± 20.58 | -0.6 ± 35.24 | -5.3 ± 30.06 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,121,127) | -8.9 ± 19.56 | -8.7 ± 19.13 | -5.4 ± 15.83 |
| Cycle 7 - approximately Month 7 (n=96,109,112) | -9.0 ± 20.64 | -9.7 ± 23.25 | -6.0 ± 20.81 |
| Cycle 10 - approximately Month 10 (n=85,91,95) | -7.9 ± 23.00 | -7.1 ± 23.85 | -5.4 ± 18.79 |
| Cycle 13 - approximately Month 13 (n=72,73,82) | -7.2 ± 25.91 | -8.8 ± 24.90 | -6.3 ± 21.84 |
| Cycle 16 - approximately Month 16 (n=62,51,62) | -10.5 ± 23.87 | -5.9 ± 25.79 | -3.3 ± 20.67 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=113,120,125) | 1.3 ± 13.37 | 0.1 ± 13.28 | 0.6 ± 12.67 |
| Cycle 7 - approximately Month 7 (n=95,108,111) | 0.4 ± 15.22 | -1.7 ± 14.27 | 1.8 ± 12.94 |
| Cycle 10 - approximately Month 10 (n=85,89,94) | -1.6 ± 14.46 | 0.0 ± 15.99 | 0.3 ± 12.61 |
| Cycle 13 - approximately Month 13 (n=72,72,81) | -3.8 ± 15.61 | -1.0 ± 14.59 | 0.3 ± 12.60 |
| Cycle 16 - approximately Month 16 (n=62,50,61) | -2.1 ± 14.95 | -2.9 ± 14.16 | -0.9 ± 12.23 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=112,121,124) | 4.7 ± 23.74 | 4.3 ± 23.56 | 7.6 ± 22.38 |
| Cycle 7 - approximately Month 7 (n=93,108,112) | 14.6 ± 24.45 | 7.7 ± 23.86 | 9.8 ± 20.62 |
| Cycle 10 - approximately Month 10 (n=83,88,97) | 17.3 ± 27.84 | 6.6 ± 22.40 | 14.5 ± 21.73 |
| Cycle 13 - approximately Month 13 (n=71,73,81) | 17.3 ± 27.15 | 6.3 ± 23.78 | 11.9 ± 24.67 |
| Cycle 16 - approximately Month 16 (n=62,52,62) | 18.5 ± 25.30 | 7.7 ± 28.49 | 14.4 ± 26.62 |
Data as of 11 May 2010 cutoff. EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image.
| units on a scale | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Cycle 4 - approximately Month 4 (n=110,117,119) | 2.1 ± 35.36 | -0.3 ± 37.27 | 4.5 ± 25.65 |
| Cycle 7 - approximately Month 7 (n=88,104,108) | 3.8 ± 33.32 | 2.6 ± 37.94 | 5.2 ± 27.78 |
| Cycle 10 - approximately Month 10 (n=79,83,94) | 7.6 ± 33.32 | -4.0 ± 43.69 | 3.9 ± 26.72 |
| Cycle 13 - approximately Month 13 (n=68,72,79) | 1.0 ± 31.01 | -0.5 ± 44.23 | 5.1 ± 32.51 |
| Cycle 16 - approximately Month 16 (n=59,52,61) | 3.4 ± 32.58 | 6.4 ± 41.25 | 2.7 ± 28.08 |
Collected over Up to 169 weeks (Double-blind therapy period plus 4 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MPR+R | — | 66/150 (44%) | 149/150 (99.3%) |
| MPR+p | — | 62/152 (40.8%) | 151/152 (99.3%) |
| MPp+p | — | 56/153 (36.6%) | 152/153 (99.3%) |
| Event | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 9/150 | 2/152 | 0/153 |
| PneumoniaInfections and infestations | 4/150 | 8/152 | 8/153 |
| AnaemiaBlood and lymphatic system disorders | 5/150 | 8/152 | 2/153 |
| PyrexiaGeneral disorders | 6/150 | 2/152 | 7/153 |
| NeutropeniaBlood and lymphatic system disorders | 6/150 | 4/152 | 1/153 |
| Deep vein thrombosisVascular disorders | 1/150 | 6/152 | 0/153 |
| Bone painMusculoskeletal and connective tissue disorders | 3/150 | 2/152 | 6/153 |
| Atrial fibrillationCardiac disorders | 1/150 | 3/152 | 5/153 |
| FatigueGeneral disorders | 4/150 | 2/152 | 1/153 |
| VomitingGastrointestinal disorders | 4/150 | 1/152 | 3/153 |
| Event | MPR+R | MPR+p | MPp+p |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 117/150 | 116/152 | 78/153 |
| ThrombocytopeniaBlood and lymphatic system disorders | 103/150 | 100/152 | 68/153 |
| AnaemiaBlood and lymphatic system disorders | 99/150 | 91/152 | 82/153 |
| LeukopeniaBlood and lymphatic system disorders | 54/150 | 58/152 | 49/153 |
| FatigueGeneral disorders | 46/150 | 51/152 | 57/153 |
| NauseaGastrointestinal disorders | 37/150 | 39/152 | 51/153 |
| Bone painMusculoskeletal and connective tissue disorders | 46/150 | 45/152 | 51/153 |
| ConstipationGastrointestinal disorders | 49/150 | 39/152 | 37/153 |
| DiarrhoeaGastrointestinal disorders | 43/150 | 36/152 | 37/153 |
| RashSkin and subcutaneous tissue disorders | 30/150 | 42/152 | 12/153 |
| Age, Continuous(years) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Mean | 72.0 ± 5.33 | 72.1 ± 5.20 | 72.0 ± 5.26 | 72.0 ± 5.25 |
| Age, Customized(participants) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| <=75 years | 116 | 116 | 116 | 348 |
| >75 years | 36 | 37 | 38 | 111 |
| Gender(Participants) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Female | 81 | 71 | 79 | 231 |
| Male | 71 | 82 | 75 | 228 |
| Race/Ethnicity, Customized(participants) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| White | 151 | 151 | 151 | 453 |
| Black | 1 | 0 | 0 | 1 |
| Hispanic | 0 | 0 | 1 | 1 |
| Asian / Pacific Islander | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Other | 0 | 2 | 2 | 4 |
| Weight(kilograms) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Mean | 73.5 ± 14.77 | 72.0 ± 12.79 | 72.1 ± 15.20 | 72.5 ± 14.28 |
| Height(centimeter) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Mean | 164.8 ± 9.81 | 165.3 ± 9.33 | 165.7 ± 9.79 | 165.3 ± 9.63 |
| Systolic Blood Pressure(mmHg) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Mean | 133.9 ± 17.71 | 135.5 ± 18.60 | 136.4 ± 20.13 | 135.3 ± 18.83 |
| Diastolic Blood Pressure(mmHg) | MPR+R | MPR+p | MPp+p | Total |
|---|---|---|---|---|
| Mean | 78.5 ± 9.53 | 77.4 ± 9.99 | 78.8 ± 10.40 | 78.2 ± 9.98 |
10 further baseline measures are reported on the registry.
The record gives a start of Jan 2007, a primary completion of Nov 2009 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide